The environment in which breast cancer arises—the interplay between the patient's BMI, tumor size and cancer-specific proteins—is of importance for the prognosis. This is shown in a study from Lund University in Sweden. ...
Aug 25, 2022
0
4
The highly selective RET inhibitor pralsetinib was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive cancers regardless of tumor type, according to results from the international ...
Aug 12, 2022
0
36
The U.S. Food and Drug Administration has approved Enhertu (am-trastuzumab-deruxtecan-nxki), an intravenous infusion treatment for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low ...
Aug 9, 2022
0
20
Long-term follow up of patients with extensive stage small cell lung cancer who were given pembrolizumab and etoposide/platinum (EP) versus placebo + etoposide/platinum as first-line therapy support the continued exploration ...
Aug 9, 2022
0
7
Like the hardiest weed, glioblastoma almost always springs back—usually within months after a patient's initial brain tumor is surgically removed. That is why survival rates for this cancer are just 25 percent at one year ...
Aug 8, 2022
0
1770
The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non-small cell lung cancer without disease progression after either concurrent chemoradiotherapy ...
Aug 8, 2022
0
2
Results of an international clinical trial co-led by researchers at Winship Cancer Institute at Emory University show potential for a novel drug to benefit patients with multiple myeloma whose disease either recurred or was ...
Aug 3, 2022
0
1509
AL amyloidosis is a life-threatening disease related to bone marrow cancer and multiple myeloma. It is caused when a person's antibody-producing white blood cells (i.e. plasma cells) do not function properly and generate ...
Jul 14, 2022
0
3
Under the direction of Boyd Professor Nicolas Bazan, MD, Ph.D., scientists at LSU Health New Orleans Neuroscience Center of Excellence have developed a new, experimental human cell line from retinal pigment epithelial cells. ...
Jul 12, 2022
0
71
A Phase II clinical trial of poziotinib for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 mutations, led by researchers at The University of Texas MD Anderson Cancer Center, found ...
Jul 11, 2022
0
6
